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Abstract 14	
RING-BETWEENRING-RING (RBR) E3 ligases are a class of ubiquitin ligases 15	
distinct from RING or HECT E3 ligases. An important RBR is Parkin, mutations in 16	
which lead to early onset hereditary Parkinsonism. Parkin and other RBRs share a 17	
catalytic RBR module, but are usually autoinhibited and activated via distinct 18	
mechanisms. Recent insights into Parkin regulation predict large, unknown 19	
conformational changes during activation of Parkin. However, current data on active 20	
RBRs are in the absence of regulatory domains. Therefore, how individual RBRs are 21	
activated, and whether they share a common mechanism remains unclear. We now 22	
report the crystal structure of a human Parkin-phosphoubiquitin complex, which 23	
shows that phosphoubiquitin binding induces a movement in the IBR domain to 24	
reveal a cryptic ubiquitin binding site.  Mutation of this site negatively impacts on 25	
Parkin’s activity. Furthermore, ubiquitin binding promotes cooperation between 26	
Parkin molecules, suggesting a role for interdomain association in RBR ligase 27	
mechanism.   28	
  29	
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 30	
Introduction 31	
Parkinson’s Disease (PD) is a neurodegenerative disorder characterised by the 32	
progressive loss of dopaminergic neurons, bradykinesia and tremor 1. Although 33	
primarily a sporadic disorder, mutations in several genes are associated with different 34	
Parkinsonism syndromes 2, including the genes PARK2 and PARK6 which lead to 35	
autosomal recessive juvenile Parkinsonism (ARJP) 3,4.  PARK2 and PARK6 encode 36	
Parkin E3 Ubiquitin ligase and PTEN-induced kinase (PINK-1), respectively, and 37	
maintain mitochondrial homeostasis 5-8. In addition to its role in mitochondrial protein 38	
control, Parkin also regulates protein degradation and induces aggresome formation 39	
by K63-linked ubiquitination 9-11. 40	
Parkin belongs to the RBR E3 ubiquitin ligase family, characterised by a RING 41	
domain (RING1) followed by an ‘in-between RING’ (IBR) domain and a catalytic 42	
domain (RING2 or Rcat 12). RING1 is structurally similar to canonical RING-type E3 43	
ligases, and shares the function of binding to E2 ubiquitin conjugating enzymes. In 44	
contrast, RING2(Rcat) adopts a linear zinc-binding fold 13,14 and possesses a catalytic 45	
cysteine capable of forming a thioester bond with activated ubiquitin 13,15-19. The 46	
linking ‘IBR’ domain adopts the same fold as the RING2(Rcat) 20, however its 47	
functional role remains unclear. RBR ligases contain additional domains outwith the 48	
RBR module. Parkin has an N-terminal ubiquitin-like domain (UBL), which shares 49	
65% homology with ubiquitin, and a zinc-binding RING0 or unique parkin domain 50	
(UPD) 21. Parkin adopts an autoinhibited conformation mediated by multiple domain-51	
domain interactions 22-26. This autoinhibition is released by PINK1-dependent 52	
phosphorylation of ubiquitin and the UBL domain of Parkin, leading to activation of 53	
Parkin 27-32. Additional RBR ligase family members include HOIP, which is a subunit 54	
of the linear ubiquitin chain assembly complex (LUBAC) 33, and the human 55	
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homologue of Ariadne, HHARI 34. The catalytic activity of HOIP is also regulated 56	
through autoinhibition, mediated by its UBA domain, which interacts with the other 57	
subunits of LUBAC, HOIL-1L and SHARPIN to activate HOIP 17,33,35,36. HHARI is 58	
also autoinhibited, mediated through its Ariadne domain 37. HHARI activation 59	
requires interaction of the UBA domain of HHARI with NEDD8 38,39. Thus our 60	
current understanding of Parkin and other RBRs suggests distinct modes of 61	
regulation. In the case of Parkin, we and others have shown that the binding of 62	
phosphoubiquitin, leads to Parkin activation via removal of the inhibitory effect of the 63	
Ubl domain 23,24,40-43. However, all the structural insights into Parkin are in the context 64	
of the autoinhibited state 23-25, or in the absence of the regulatory Ubl domain 16,25,26,43. 65	
Insights into HHARI are also based on an inactive conformation  37.  Recent insights 66	
into the catalytic mechanism of the RBR family have come from structural and 67	
physical analyses of HOIP 14,44.  The crystal structure of the catalytic RING2-Like 68	
(RING2L) or Rcat domain of HOIP in complex with ubiquitin revealed how linear 69	
chains are assembled 14, while a recent complex of the RBR module of HOIP in 70	
complex with a charged E2~ubiquitin conjugate revealed a series of allosteric 71	
ubiquitin-binding sites coupled to a swapped dimer of the RING2L(Rcat) domain 72	
between RBR molecules44. Furthermore, the RING2(Rcat) of HHARI has a ubiquitin 73	
binding site important for E2~ubiquitin recruitment 45, and the RING1 of HHARI 74	
supports an open conformation of the E2~ubiquitin conjugate. In contrast a structure 75	
of the RING0-RBR (R0RBR) domains from Pediculus	humanus	corporis Parkin, in 76	
complex with phosphoubiquitin does not show domain swapping between RBR 77	
modules, but rather revealed a conformational change in the IBR domain upon 78	
phosphoubiquitin binding 43. Our current understanding is derived from snapshots of 79	
individual domains of large multidomain complexes. However, how RBR ligases 80	
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function in the context of their regulatory domains remains unclear, and whether they 81	
share a universal catalytic mechanism remains unclear. 82	
We report here the crystal structures of activated human Parkin (UblR0RBR), and a 83	
phosphomimic Parkin (S65DUblR0RBR), in complex with phosphoubiquitin, at 2.7 84	
and 2.6 Å resolution respectively. All Parkin domains are present, and in contrast to 85	
earlier predictions of large conformational rearrangements upon activation, the Parkin 86	
structures reveal subtle, local changes that result in a series of cryptic ubiquitin or 87	
ubiquitin-like binding regions that are essential for Parkin function. We find an 88	
essential role of the IBR domain in ubiquitin recruitment and Parkin activity. 89	
Furthermore, comparative analyses with the HOIP and HHARI modules reveals 90	
common ubiquitin or ubiquitin-like binding sites. In particular, comparison with the 91	
RBR of HOIP suggests a potential unifying mechanism of cooperation between 92	
multiple RBR modules in the mechanism of ubiquitin ligase activity. 93	
 94	
Results 95	
Crystal structure of UBLR0RBR Parkin in complex with pUb reveals activated 96	
state of Parkin 97	
Previous studies by ourselves and others suggest that binding of 98	
phosphoubiquitin to Parkin relieves the autoinhibition by the UBL domain. Consistent 99	
with this, the UBL domain displays weaker binding to the R0RBR fragment of Parkin 100	
in trans upon phosphoubiquitin binding 23,24,40-43,46. In order to understand the 101	
allosteric regulation by phosphoubiquitin, we crystallised a complex of Parkin 102	
UBLR0RBR (Δ84-143) with a phosphoubiquitin (pUb) suicide probe (pUb3BR, pUb	103	 bromopropylamine). To enable the formation of stable, well diffracting crystals, we 104	
generated a covalent Parkin-pUb complex by ligating the pUb3BR probe to a cysteine 105	
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residue on the surface of Parkin. The cysteine was provided by mutating Gln347, as 106	
described previously 43. The structure of activated Parkin was refined to 2.7 Å (Table 107	
1), with good geometry and refinement statistics. The crystal structure of the Parkin-108	
pUb complex reveals the activated state of Parkin, containing all 5 domains of Parkin 109	
UBL, RING0, RING1-IBR-RING2(Rcat) and pUb (Fig 1a).  In the asymmetric unit, 110	
UBL, RING1-IBR-RING2(Rcat) are contributed from one molecule whereas RING0 111	
and pUb are from another molecule, with the biological unit via symmetry related 112	
molecules (Supp Fig 1a). Comparison of the activated state of Parkin-pUb with the 113	
apo, inactive UBLR0RBR structure 23 shows that although some small 114	
rearrangements occur, the UBL-RING1 interface, primarily formed by between β3 115	
and β5 of the UBL domain, and helix H1 of the RING1 domain, remains largely 116	
intact in the presence of phosphoubiquitin (Fig 1b). The largest structural 117	
rearrangement upon activation is the movement of the IBR domain. Helix H3 of the 118	
RING1 domain straightens, leading to global movement of the IBR domain 119	
(henceforth this helix is referred to as H3-IBR), and creating a void between the UBL 120	
and IBR domains. This straightening of the H3-IBR helix is also observed in the 121	
insect Parkin R0RBR complex with pUb that lacks the UBL domain 43. In the apo 122	
structure this UBL-IBR interface is formed primarily through interactions of His11 of 123	
the UBL domain with Lys369, Glu370 of the IBR domain, and surrounding residues, 124	
and these interactions are lost in the phosphoubiquitin-bound complex. 125	
Phosphorylation of the UBL domain by PINK-1 has been shown to weaken 126	
association of the UBL domain with R0RBR Parkin 23,24,42,46,47. Therefore, we 127	
wondered whether inclusion of a negative charge at Ser65 to mimic phosphorylation 128	
would lead to displacement of the UBL domain in presence of pUb. To test this, we 129	
crystallised a covalent complex of S65D-UBLR0RBR Parkin with the pUb suicide 130	
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probe. In this structure, refined to 2.6 Å resolution, the S65D-UBL domain remains 131	
associated with RING1 (Supp Fig.1b). However, there are local conformational 132	
rearrangements between UBLR0RBR/S65SD-UBLR0RBR in complex with pUb and 133	
the apo structure of UBLR0RBR. In the apo structure of UBLR0RBR, residues 383-134	
390, part of the tether that connects the IBR domain to the Repressor Element of 135	
Parkin (REP) are disordered 23,25. In contrast, this tether, residues 387-390, is ordered 136	
and traceable in the WT Parkin-pUb complex, with Arg392 pointing towards the 137	
disordered side-chain of Lys48 in the UBL domain. This Arg392-Lys48 creates an 138	
electrostatic repulsion, while Gln389 and Tyr391 cement the association of the UBL-139	
RING1 interface, resulting in flexibility of the 62-65 loop in the UBL domain (Supp 140	
Fig 1b). Upon inclusion of a negative charge at position 65, Tyr391 relocates from the 141	
UBL-RING1 interface, resulting in disorder of the IBR-REP tether and ordering of 142	
the 62-65 loop in the UBL domain (Supp Fig 1c). We wondered whether mutation of 143	
these residues would enable the UBL domain to bind ΔUBL-Parkin in the presence of 144	
pUb. In the absence of pUb, the UBL domain associates with ΔUBL-Parkin (80-465) 145	
with a dissociation constant (Kd) in the low micromolar range 22-24,43 (Supp Fig 1d). 146	
The presence of pUb blocks the UBL interaction with ΔUBL- Parkin (Supp Fig 1d). 147	
Gln389Ala, Tyr391Ala and Arg392Ala mutation in ΔUBL-Parkin does not permit 148	
UBL re-association in the presence of pUb (Supp Fig 1d). Given that the structures 149	
clearly show the UBL-RING1 interface persists in the presence of pUb, we wondered 150	
whether the loss of association in solution could be due to a weakened UBL-IBR 151	
interface (Fig 1B), rather than UBL-RING1 interface.  To test this, we expressed and 152	
purified human Parkin lacking the IBR domain, and measured the interaction of the 153	
UBL domain with Parkin, using isothermal titration calorimetry (ITC).  The UBL 154	
domain does not associate with ΔUBL-ΔIBR (80-329,383-465) (Fig 1c). In order to 155	
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understand the role of the IBR domain we assayed this mutant for E3 ligase activity. 156	
ΔUBL-Parkin is active, both in the absence and presence of phosphoubiquitin (Fig 157	
1d). In contrast, deletion of the IBR domain in ΔUBL-Parkin leads to complete loss of 158	
Parkin activity, which cannot be rescued by the addition of pUb.  It is a possibility 159	
that removal of the IBR domain results in a constrained version of Parkin that lacks 160	
the flexibility needed for maintenance of its catalytic domains. In order to rule this 161	
possibility out, we purified ΔUBL-ΔIBR containing a 10-residue (Gly-Thr-Ser-Gly-162	
Thr-Ser-Gly-Ser-Ala-Ser) (ΔUBL-ΔIBRxL10) linker to span the 28 Å distance 163	
required, and assayed for ubiquitination activity (Fig 1d). These constructs lacking the 164	
IBR domain are folded, monodisperse and migrate at the expected molecular weight, 165	
consistent with folded proteins. In contrast to wild-type and ΔUBL-Parkin, both 166	
ΔUBL-ΔIBR and ΔUBL-ΔIBRxL10 Parkin lack ubiquitination activity, even in the 167	
presence of phosphoubiquitin. Interestingly, the surface of the UBL domain when 168	
phosphorylated would result in repulsion with the negatively charged surface of IBR, 169	
supporting a weakened UBL-IBR interaction (Supp Fig 1e). The observation that the 170	
UBL domain and pUb both interact with IBR, on opposite sides, could explain the 171	
competitive mode of binding to Parkin that has previously been observed 23,24. Taken 172	
together, these results show that activation of Parkin by phosphoubiquitin binding 173	
involves loosening of the UBL-IBR interface, caused by a straightening of the H3-174	
IBR helix. Furthermore, these experiments show that the association of the UBL 175	
domain with the rest of Parkin depends upon the presence of the IBR domain in 176	
addition to the more extensive RING1 surface, and that Parkin activity requires an 177	
intact IBR domain. 178	
 179	
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Parkin activation exposes ubiquitin or ubiquitin-like binding surfaces that are 180	
essential for Parkin activity 181	
 The straightening of the H3-IBR helix caused by phosphoubiquitin binding 182	
results in a void being created between the UBL and IBR domains (Supp Fig 2a).  183	
Intriguingly, analysis of the crystal packing of activated Parkin reveals that this void 184	
is occupied by the UBL domain of another molecule of Parkin (Supp Fig 2b). The 185	
UBL domain of Parkin shares 65% sequence similarity with ubiquitin. We therefore 186	
wondered whether the void created by the loosening of the UBL-IBR interaction, 187	
occupied in our crystal structures by the UBL domain of a second molecule of Parkin, 188	
could accommodate ubiquitin. To explore this idea, we modelled ubiquitin into the 189	
void (Fig 2a). This arrangement reveals potential surfaces on Parkin that could 190	
interact with ubiquitin, referred to as Ubiquitin Binding Region (UBR) 1,2, and 3, 191	
respectively (Fig 2). UBR1 is contributed by the UBL domain of Parkin, mediated by 192	
His11, Phe13, Arg33, Gln34 (Fig 2b). Mutation of UBR1 residues on Parkin results in 193	
a minor reduction in ubiquitin chain formation, but no observable decrease in 194	
substrate ubiquitination, in this case Miro1 (Fig 2b). UBR2 and UBR3 are formed on 195	
the straightened helix (H3) of RING1 and the IBR of Parkin, respectively. The 196	
potential ubiquitin binding surfaces are mediated by Arg275, Gln317, Tyr318, Glu321 197	
on H3 of RING1, and Arg334 and Pro335 of the β-hairpin on IBR (Fig 2c). Mutations 198	
in UBR2 (R275A, Y318A, E321A) and UBR3 (R334A) result in loss of E3 ligase 199	
activity, both in ubiquitin chain formation and Miro1 ubiquitination (Fig 2c). 200	
Therefore, UBR2 and UBR3, but not UBR1, are important for Parkin activity. In 201	
order to further clarify which regions of activated Parkin interact with ubiquitin, we 202	
performed NMR chemical shift perturbation experiments of the R0RBR fragment of 203	
Parkin in complex with pUb (Fig 2d). Upon addition of unlabelled Ub to the R0RBR-204	
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pUb complex it was clear that the IBR domain was a major site of interaction. The 205	
largest chemical shift changes occur for residues G329-R334 of the β-hairpin and the 206	
adjoining loop (G361-A363, R366) of the IBR domain. Changes were also observed 207	
in the straightened helix (H3) of RING (R314, V324) near those observed in the 208	
crystal structure. However, several of these resonances are broadened by pUb binding 209	
and are therefore difficult to visualise in the NMR spectra. Nevertheless, this analysis 210	
shows a large ubiquitin interaction surface in activated Parkin that is consistent with 211	
that for UBR2 and UBR3 sites predicted from the crystal packing analyses. These 212	
findings suggest a role for ubiquitin (or ubiquitin-like protein) binding at surfaces 213	
exposed upon pUb binding in the regulation of Parkin activity. Consistent with this, a 214	
recent study shows that modification of the IBR domain at Lys349 and Lys369 by the 215	
ubiquitin-like protein ISG15, positively regulates Parkin activity 48. Interestingly, 216	
Lys349 is also a target of Parkin autoubiquitination activity 13. Therefore, we 217	
wondered whether Parkin modification by ubiquitin can influence Parkin activity. To 218	
explore this possibility, we generated a covalently linked Parkin carrying a ubiquitin 219	
chain (UBLR0RBR347Cys~pUb-M1-(UBS65A)3, to mimic polyubiquitinated Parkin. 220	
In comparison with UBLR0RBR347Cys~pUb or providing pUb to UBLR0RBR in 221	
trans, UBLR0RBR347Cys~pUb-M1-(UBS65A)3 activity is dramatically enhanced 222	
(Supp Fig 2c). Taken together, these data suggest an important role for the 223	
displacement of the UBL-IBR interface, revealing that modification of the IBR, 224	
phosphorylation of Ser65 in the UBL-IBR interface, and pUb binding to the IBR 225	
domain all contribute to the creation of a ubiquitin/ubl binding region, and that 226	
ubiquitin binding stimulates Parkin activity. 227	
 228	
The UBL-IBR ubiquitin binding site recruits the donor ubiquitin 229	
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The arrangement of phosphoubiquitin of one molecule of Parkin, and the UBL 230	
domain of a second molecule, is reminiscent of the activator ubiquitin and donor 231	
ubiquitin recently described in the structure of the RBR of HOIP in complex with a 232	
charged E2 44 (Fig 3a). Furthermore, UbcH7 interaction with phosphorylated Parkin is 233	
enhanced 20 fold by the addition of phosphoubiquitin and charging of the E2 with 234	
ubiquitin 23,49. Thus we wondered whether the ubiquitin binding site created from the 235	
activation of Parkin by phosphoubiquitin could accommodate the charged 236	
E2~ubiquitin conjugate. To test this, we measured UbcH7 or UbcH7~ubiquitin 237	
interaction with phosphoparkin (pParkin) or a UBR2 mutant pParkinE321A, in the 238	
presence of pUb. ITC experiments show a similar affinity of pParkin or 239	
pParkinE321A for UbcH7 (Kd of 19 and 23.5 µM respectively) in the presence of 240	
pUb, suggesting that mutation of the ubiquitin binding region of Parkin does not 241	
interfere with E2 binding (Fig 3b). In contrast, while phosphoParkin binds to 242	
UbcH7~ubiquitin with a 30-fold higher affinity, this enhanced binding is diminished 243	
for phosphoParkinE321A (~2.5 fold) (Fig 3b). In addition, size exclusion 244	
chromatography of these complexes reveals that mutation of E321 to alanine 245	
abolishes formation of the phosphoParkin UbcH7~Ub complex in the presence of 246	
phosphoubiquitin (Supp Fig 3a). We ruled out the possibility that mutation of E321 247	
leads to loss of phosphoubiquitin binding by ITC measurement (Supp Fig 3b). These 248	
data suggest that the ubiquitin carried by charged E2 binds at the UBR regions in 249	
activated Parkin. Previous studies have shown that when the only source of ubiquitin 250	
is phosphoubiquitin, Parkin cannot catalyse ubiquitin chains 49,50. However, UbcH7 251	
can be charged with pUb 50. Furthermore, measurements of Parkin fragments 252	
interacting with either ubiquitin or pUb showed a similar isotherm profile, but with 253	
much tighter binding to pUb 23. Both these observations suggest that the pUb-binding 254	
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pocket on the surface of Parkin is the dominant ubiquitin binding site. Therefore we 255	
wondered whether loading of E2 with pUb redirects the conjugate to the pUb binding 256	
site on the Parkin, rather than going to the donor ubiquitin binding site. To test this, 257	
we “activated” Parkin using either pUb, or UbcH7 charged with pUb (Ubch7~pUb). 258	
Interestingly, UbcH7~pUb, but not UbcH7~ubiquitin, activates Parkin to a similar 259	
extent as pUb alone (Fig 3c). Taken together, these data suggest that the cryptic 260	
ubiquitin binding site created between the UBL-IBR domains upon Parkin activation, 261	
recruits the donor ubiquitin as carried by the E2. 262	
 263	
Cooperation between multiple Parkin molecules promotes ubiquitin transfer 264	
Using the position of the UBL domain, the HOIP RBR/E2~Ub structure, and 265	
the chemical shift perturbations on Parkin as guides, we modelled an activated Parkin-266	
donor ubiquitin complex (Supp Fig 4a). In the model, with only one molecule of 267	
Parkin, it is difficult to envision how the E2 of the E2~Ub conjugate would reach the 268	
proposed E2 binding site at the base of the RING1. In addition, it is difficult to 269	
determine how the ubiquitin would reach the catalytic cysteine in the RING2(Rcat). 270	
Indeed, despite many efforts to understand how the catalytic cysteine in the 271	
RING2(Rcat) domain mechanistically directs Parkin activity, previous Parkin 272	
structures show that the Cys431 of the RING2(Rcat) domain is ~35 Å away (using the 273	
sulfur of Cys431, and the side-chain oxygen of Thr240 as the reference points) from 274	
the predicted E2 binding site on RING1 25. Furthermore, multiple groups have 275	
reported that Cys431 is occluded by RING0 16,25,26. In our crystal structure of the 276	
Parkin-pUb complex, one molecule of activated Parkin accommodates a UBL domain 277	
from a neighbouring molecule, which we model as donor ubiquitin. This modelled 278	
donor ubiquitin packs against the catalytic RING2(Rcat) domain of a neighbouring 279	
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Parkin molecule (Fig 4a). This quarternary arrangement of Parkin molecules can also 280	
accommodate an E2, with proposed interactions with the RING1 and REP of 281	
molecule 2, satisfying observed E2 interaction sites in HOIP and HHARI 44,45 (Fig 282	
4a). Therefore, we wondered whether the UBR2 donor ubiquitin binding site would 283	
affect the loading on ubiquitin onto the catalytic cysteine (C431). In order to test this, 284	
we designed an in vitro assay that evaluates the transfer of donor ubiquitin from the 285	
E2 to the RBR catalytic residue. First, we generated a Parkin RING2(Rcat) mutant, 286	
able to trap the catalytic Parkin~Ub intermediate 13,17, referred to as R0RBRCH. This 287	
species has a serine in place of the catalytic cysteine (C431S) and a His433Ala 288	
mutation in order to trap an ester-bound ubiquitin and impede any subsequent 289	
discharge. This R0RBRCH Parkin species can be charged with ubiquitin and was 290	
sensitive to sodium hydroxide hydrolysis thus confirming the RING2(Rcat)-ubiquitin 291	
ester link. The addition of phosphoubiquitin in this setup greatly enhances the 292	
RING2(Rcat) charging by around 7-fold while a catalytic Cys431Ala mutant (R0RBR 293	
C431A) Parkin cannot be charged with ubiquitin in either scenario (Fig 4b). We then 294	
generated a UBR2 patch mutant of Parkin in this background, R0RBRCH E321A. In 295	
contrast to R0RBRCH, this mutant is defected in ubiquitin charging even in the 296	
presence of phosphoubiquitin (26-fold less). Finally, a combined mutant of the 297	
phosphoubiquitin patch and the UBR2 patch (R0RBRCH H302A+E321A) was 298	
drastically reduced (60-fold less) in ubiquitin charging of the RING2(Rcat) (Fig 4b). 299	
Recent studies have suggested a physiological role for self-association of Parkin 300	
molecules. For example, in 2013, two independent studies reported the observation 301	
that catalytically compromised Parkin (C431 mutants) could not translocate to the 302	
mitochondria after PINK1 activation 15,19. However, co-expression of C431 mutant 303	
Parkin with either wild-type Parkin, or other mutations including the R275W that 304	
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would affect the UBR2 binding site, could rescue this translocation defect. These 305	
observations raise the possibility of cooperation between Parkin molecules. We have 306	
demonstrated that mutation of the donor ubiquitin binding site UBR2 in Parkin results 307	
in loss of Miro1 ubiquitination (Fig 2c). Thus we wondered whether a constitutively 308	
phosphoubiquitin-bound form of Parkin could support the activity of otherwise 309	
inactive Parkin, in this case phosphoParkinE321A. To test this, we took the 310	
crystallised species of Parkin UblR0RBR covalently linked to phosphoubiquitin, and 311	
titrated it into phosphoParkinE321A (Fig 4c).  We find that wild-type phosphoParkin 312	
can ubiquitinate Miro1 (Fig 4c). Addition of UblR0RBR, or UblR0RBR covalently 313	
complexed with pUb does not further enhance this activity. In contrast, 314	
phosphoParkinE321A is defective in Miro1 ubiquitination (Fig 4c). Addition of 315	
autoinhibited UblR0RBR does not significantly enhance Miro1 ubiquitination (Fig 4c, 316	
Supp Fig 4b). However, addition of equimolar amounts of active UblR0RBR 317	
complexed with pUb rescues Miro1 ubiquitination to a greater extent than having the 318	
UblR0RBR.pUb complex alone (Fig 4c). These data suggest that the activity of 319	
inactive Parkin molecules can be stimulated by the presence of activated Parkin 320	
molecules. Taken together, these data demonstrate that Parkin molecules can function 321	
together to ligate ubiquitin. 322	
 323	
 324	
Discussion 325	
Previous extensive characterisation of Parkin has shown that Parkin exists in 326	
an autoinhibited state, mediated through multiple domain-domain interactions, 327	
including the UBL-RING1 interface, the REP blocking the proposed E2 binding site, 328	
and the proposed occlusion of the catalytic cysteine, Cys431, by the RING0 domain 329	
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16,22-26. All these inhibitory mechanisms are relieved by the activation of Parkin by 330	
pUb 27,28,30. pUb and the phosphorylated UBL domain are unable to simultaneously 331	
bind to R0RBR Parkin in solution, in trans, suggesting an allosteric regulation of 332	
Parkin by pUb binding 23,24,42,46. In addition, previous studies have led to predictions 333	
of large conformational changes in Parkin upon activation. Interestingly, a 334	
computational analysis of Parkin suggest that phosphorylation of the UBL domain 335	
initiates a large change, mediated by the 65 amino acid linker between the UBL 336	
domain and RING0 (residues 77-140) 47. An important caveat of our current 337	
understanding of the mechanism of Parkin activity is that structures are either of 338	
fragments of Parkin (R0RBR) 16,25,26, or all domains but lacking the UBL-RING0 339	
linker 23,24. However, in a low resolution structure of full length rat Parkin, the linker 340	
is present in the protein, but is completely disordered in the crystal and can’t be 341	
modelled 25. The UBL domain and R0RBR domains remain as they are in the absence 342	
of the linker 23,24. Interestingly, while the linker length, although not the composition, 343	
is conserved down to Drosophila 23,24, Parkin from nematodes does not have a long 344	
linker between the UBL and RING0 domains, therefore the functional importance of 345	
this linker is still unclear. In this study, we present a modified model for Parkin 346	
regulation, based on the first structures of an RBR ligase in the activated state, 347	
complete with regulatory domains. Our structures reveal that in contrast to the large 348	
conformational changes that have been predicted for Parkin function, activation of 349	
Parkin results in local rearrangements of Parkin domains to reveal ubiquitin binding 350	
sites. These ubiquitin binding sites recruit molecules of ubiquitin, or ubiquitin carried 351	
by an E2, to bridge Parkin molecules and allow the utilisation of catalytic domains 352	
from neighbouring molecules. In this model, the UBL-IBR interaction (Fig 5a) is 353	
perturbed by UBL phosphorylation or pUb binding, displacing the IBR from the UBL 354	
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domain (Fig 5b/c). This IBR displacement opens a ubiquitin binding pocket on the 355	
helix (H3)-IBR surface. A (donor) ubiquitin on loaded E2 occupies this new pocket 356	
while E2 occupies the proposed sites on RING1, and the RING2(Rcat) of the 357	
neighbouring molecule of Parkin (Fig 5d).  358	
Based on current data, Parkin is unique in the RBR family in that it has a 359	
distinct structural arrangement of RING1-IBR-RING2(Rcat) domains, where 360	
RING2(Rcat) and RING1 are in juxtaposition. In contrast, in HOIP and HHARI 361	
RING2(Rcat) and RING1 are separated by IBR (Supp Fig 5a) 37,44. Although RBRs 362	
share a conserved catalytic RING1-IBR-RING2(Rcat) module, they are usually 363	
autoinhibited and activated via distinct mechanisms. pUb binding or UBL 364	
phosphorylation releases Parkin autoinhibition 27-32, HOIP autoinhibition is released 365	
by UBA mediated interactions with LUBAC constituents HOIL-1L or SHARPIN 366	
22,29,30,33,36,38,51 and HHARI autoinhibition is released by NEDD8 binding at the UBA 367	
38. In the structure of full-length HHARI, the proposed NEDD8 binding pocket (Supp 368	
Fig 5b) corresponds to the pocket is occupied by pUb or allosteric ubiquitin (Uballo) in 369	
active Parkin or HOIP, respectively. This suggests that NEDD8 binding to HHARI 370	
would have a similar effect as pUb or Uballo binding has on Parkin and HOIP. Inactive 371	
HHARI and Parkin have a compact H3-IBR region (Supp Fig 5c). Active Parkin and 372	
HOIP structures enable pUb or Uballo binding on one side of the H3-IBR region which 373	
in the case of Parkin is occluded when inactive, and allows donor ubiquitin binding on 374	
the opposite side of the H3-IBR (Supp Fig 5d). Therefore, we speculate that blocking 375	
the donor ubiquitin binding site on one side of the H3-IBR, relieved upon pUb or 376	
Uballo binding on the opposite side via opening of the H3-IBR to allow donor 377	
ubiquitin binding, could be a common mechanism of regulation in RBR ligases. 378	
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The structure of HOIP-RBR in complex with loaded E2 also suggests that the 379	
RING1 and RING2(Rcat) of the same molecule cannot crosstalk as they are not close 380	
enough to allow catalysis of thioester formation, mediated by the catalytic cysteines 381	
of E2 and RING2(Rcat) (Supp Fig 5e). In the active state of HOIP-RBR the 382	
processive unit is formed by the RING2(Rcat) of molecule 1, and the RING1-IBR of 383	
a second molecule, where E2 interacts with the RING2(Rcat) of molecule 1 and 384	
RING1 of molecule 2 whereas the donor ubiquitin interacts with the RING2(Rcat) of 385	
molecule1 and the H3-IBR of molecule 2 (Supp Fig 5e). In contrast, in Parkin the 386	
processive unit is formed by RING1-RING2(Rcat) of molecule 1, and the IBR of 387	
molecule 2 (Fig 4d). This difference in the arrangement of domains between Parkin 388	
and HOIP, in the active state, is consistent with the differences in RING1-IBR-389	
RING2(Rcat) structural organisation in three dimensions (Supp Fig 5a). Interestingly, 390	
inter/intra-molecular pairing of RING1-RING2(Rcat)-IBR domains of RBRs with E2 391	
and donor ubiquitin explains the previous observations that Parkin and other RBRs 392	
favour the extended ‘open’ conformation of loaded E2 44,45. Furthermore, a role for 393	
Parkin oligomerisation or self-association has previously been reported 15, along with 394	
reports of Parkin having ubiquitin-binding activity 19,22. Our structures of active 395	
Parkin support the idea that PINK1 induces structural changes in Parkin that stimulate 396	
ubiquitin binding.  In the context of the mitochondrial membrane environment, where 397	
Parkin functions in mitophagy 52), high local concentrations of Parkin, recruited by 398	
PINK1-catalysed phosphorylation of ubiquitin, could result in the feed-forward 399	
amplification of Parkin-mediated ubiquitination observed at the mitochondria 52,53. 400	
Furthermore, it has been reported that Parkin functions with the linear chain assembly 401	
complex, LUBAC, comprising two RBR proteins in HOIP and HOIL-1L 54. The 402	
structures reported here open up the possibility of cooperation between RBR modules, 403	
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and therefore we speculate that there is a possibility that RBR ligases can function in 404	
concert. 405	
Within the RBR module, it has long been predicted that RING1 recruits the E2 406	
55, recently formally demonstrated for HHARI and HOIP 44,45; and that the 407	
RING2(Rcat) domain, harbouring the catalytic cysteine, is the catalytic intermediate 408	
domain 18. However, a functional role for the IBR domain has been less clear. Our 409	
observation that covalent modification in the IBR enhances Parkin activity, and that 410	
deletion of IBR or mutations in IBR leads to loss of Parkin activity, coupled with a 411	
recent report of increased Parkin activity after ISG15ylation on K349 and K363 of the 412	
IBR 48, suggest a crucial role for the IBR in Parkin function. Our study suggests that 413	
the role of the IBR, together with H3 (helix connecting RING1 and IBR), is to 414	
mediate interactions with the inhibitory UBL domain in the inactive state, and the 415	
donor ubiquitin in the active state, respectively. Furthermore, the IBR and 416	
RING2(Rcat) of RBRs are structurally similar folds, each containing two β-hairpin 417	
turns. Comparison of Parkin and HOIP structures in the active state reveals that the 418	
IBR can interact with 2 ubiquitin molecules (pUb or Uballo, and donor ubiquitin) 419	
spanning across both β-hairpins (Supp Fig 5a). Similar to the IBR, the RING2(Rcat) 420	
of HOIP also interacts with 2 ubiquitin molecules (donor and acceptor ubiquitin) 14,44 421	
mediated by both β-hairpins (Supp Fig 5f). Interestingly this observation furthers the 422	
idea that the ubiquitination process is facilitated by the inherent ability of E1, E2 and 423	
E3 proteins to interact with ubiquitin 56. In our Parkin structures, only one ubiquitin 424	
binding site is captured, predicted to be the donor ubiquitin binding site, while the 425	
acceptor ubiquitin may occupy the opposite surface, in a manner similar to HOIP 426	
(Supp Fig 5g); However, we cannot rule out that there may be subtle differences in 427	
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the acceptor ubiquitin or substrate recognition between RBRs that result in different 428	
type of modifications by different RBRs.  429	
Taken together, our data suggest a common mechanism of regulation in RBRs. 430	
First, autoinhibition via blocking a donor ubiquitin binding pocket on H3-IBR. 431	
Second, release of autoinhibition by a UBL, be that phosphoubiquitin, NEDD8, 432	
ISG15, or ubiquitin itself, opening the H3-IBR binding site. Third, donor ubiquitin 433	
binding on the H3-IBR accompanied by a bridging of RBR molecules to facilitate 434	
access to the catalytic cysteine. Given the importance of Parkin function in mitophagy 435	
and PD, understanding the multiple regulatory modes required for function will 436	
provide a framework for the design of small molecules to modulate Parkin activity.  437	
 438	
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Figure Legends 605	
Figure 1 Overall structure of Parkin-phosphoubiquitin complex in the activated 606	
state 607	
a) Crystal structure of UBLR0RBR and pUb complex showing UBL, RING0 , 608	
RING1, IBR, REP, and RING2(Rcat) of Parkin, in complex with 609	
phosphoubiquitin (blue). The phosphate group of phosphoubiquitin is shown in 610	
stick representation. 611	
b) Comparison of UBLR0RBR-pUb complex (coloured) with the apo structure of 612	
UBLR0RBR (grey) (PDB code 5C1Z 23). UBLR0RBR superimposed on the 613	
UBLR0RBR-pUb complex structure shows conformational changes between the 614	
IBR and the UBL domain, and the void formed (marked with arrow), helix 1 (H1) 615	
and helix 3 (H3) of RING1 are marked. UBL (green) remains associated with H1 616	
of RING1 (cyan) in both apo and complex structures. 617	
c) Isothermal Titration Calorimetry assays showing UBL interaction with ΔUBL 618	
Parkin (left panel), and that deletion of IBR in ΔUBL Parkin leads to loss of UBL 619	
and Parkin interaction (right panel). 620	
d) Deletion of the IBR in ΔUBL Parkin leads to loss of E3 ligase activity of 621	
Parkin in ubiquitin chain formation, Parkin autoubiquitination, and Miro1 622	
	 24	
ubiquitination. FL (autoinhibited) or ΔUBL (active) Parkin comparison is shown 623	
with ΔUBL-ΔIBR Parkin, or ΔUBL-ΔIBR with a 10-residue linker in the presence 624	
or absence of pUb. Uncropped gel images are shown in Supplementary Data Set 625	
1. 626	
 627	
Figure 2 Identification of potential ubiquitin binding regions important for 628	
Parkin function. 629	
a) Model of ubiquitin (grey surface) binding to Parkin, based on crystallographic 630	
packing of a second Parkin molecule (shown in Supp Fig 2b). The boundary of 631	
one UBLR0RBR-pUb complex (domains coloured as in Figure 1) is represented 632	
by a dashed line. 633	
b) The UBL (green) and forms ubiquitin binding region 1 (UBR1) (left panel). 634	
For clarity, UBL (green), modelled ubiquitin (grey), RING1 helices H1, H3 635	
(cyan), IBR (brown) are schematically represented below, with molecule 1 636	
boundary of Parkin marked with a dashed line, and UBR1 marked as a shaded 637	
box. The activity of UBR1 mutants was monitored by fluorescently-labelled 638	
ubiquitin incorporation into ubiquitin chains and Parkin autoubiquitination, and 639	
Miro1 ubiquitination (right panel). Coomassie-stained gel is shown as loading 640	
control. In this and in all subsequent ubiquitination assays, a non-specific, ATP-641	
independent band is indicated (*). 642	
c) H3 of RING1 (cyan) and IBR (brown) make 2 important interfaces with 643	
ubiquitin (grey) (left upper panel), shown as UBR2 (purple box) and UBR3 (red 644	
box), respectively (left lower panel). Mutations in UBR2 and UBR3 of Parkin 645	
lead to loss of E3 ligase activity of Parkin in ubiquitin chain formation, Parkin 646	
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autoubiquitination, and Miro1 ubiquitination (right panel). Assay conditions are as 647	
in panel b. 648	
d) Chemical shift perturbation map obtained from NMR titration experiments 649	
where 2H,14N-labelled Ub was titrated into a solution of 2H,12C,15N-labelled 650	
R0RBR Parkin in complex with 2H-labelled pUb, and followed by 1H,15N TROSY 651	
experiments. Residues that experienced chemical shift changes greater than 1 652	
standard deviation above the average shift in the absence of Ub are indicated in 653	
yellow. 654	
 655	
Figure 3 Parkin activation promotes donor ubiquitin (Ubdon) binding at H3-IBR 656	
interface  657	
a) Nature of interactions (red sphere: electrostatic, black sphere: hydrophobic) 658	
between pUb (blue)/UB (grey) and H3 (cyan)/IBR (brown) of Parkin are shown 659	
schematically (left panel). Residues on H3 (cyan)-IBR (brown) of Parkin 660	
interacting with pUb (blue) and Ub (grey surface) (modelled by superposition on 661	
UBL of molecule 2 in the UBLR0RBR-pUb complex structure) are shown as 662	
sticks (middle panel). Helix-connecting-RING1-IBR and IBR of HOIP interaction 663	
with activator ubiquitin (Ub) and donor ubiquitin (Ubdon) (pdb code 5EDV 44). 664	
b) Isothermal Titration Calorimetry assays showing Glu321Ala mutation does not 665	
affect Parkin interaction with UbcH7 (upper panel), but does reduce Parkin 666	
interaction with the UbcH7~Ub iso-peptide (lower panel). ITC measurements 667	
were performed using phosphorylated Parkin in the presence of pUb.  668	
c) Parkin can be activated by UbcH7C86K~pUb conjugate similarly to pUb. 669	
Ubiquitination assay was performed with 1µM of ParkinS65A. Parkin was 670	
activated with 1µM of UbS65A/pUb/UbcH7C86K~Ub/UbcH7C86K/ 671	
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UbcH7C86K~pUb (Left panel), coomassie-stained gel is shown as loading control 672	
(lower panel). A model depicting distinct ubiquitin (UbcH7~Ub or pUb/ 673	
UbcH7C86K~pUB) binding regions on Parkin is shown in the right panel. 674	
 675	
Figure 4 Parkin molecules cooperate to facilitate ubiquitin transfer 676	
       a) Model of crystal packing between molecules of Parkin. The  modelled donor 677	
ubiquitin (grey surface) sits above the catalytic cysteine (C431) of the 678	
RING2(Rcat) (red) of a neighbouring Parkin molecule. For clarity, the rest of the 679	
Parkin molecules are shown in slate, except for the UBL domain (green), and IBR 680	
(brown). The predicted E2 binding region on each molecule is shown. 681	
       b) Mutation of UBR2 and phosphoubiquitin patches of Parkin leads to defects in 682	
formation of a RING2(Rcat)-Ub ester intermediate, monitored using fluorescently-683	
labelled ubiquitin (left top). Sodium hydroxide sensitivity confirms the 684	
RING2(Rcat)-ubiquitin ester bond (left bottom). Coomassie-stained gels are shown 685	
as total Parkin levels. Integrated intensities of Parkin-Ub ester levels from three 686	
independent experiments were plotted as mean ± SEM (right). Statistical 687	
significance was determined by one-way analysis of variance with Bonferroni’s 688	
multiple-comparison test. (n = 3, ****P < 0.0001). 689	
       c) Activated UblR0RBR complexed with phosphoubiquitin can stimulate the 690	
activity of inactive Parkin. The activity of phosphoParkin mutated in the ubiquitin 691	
donor binding site (E321A) is enhanced by the addition of UblR0RBR Parkin 692	
covalently complexed with phosphoubiquitin. Addition of UblR0RBR Parkin 693	
alone does not enhance the activity of pParkinE321A. Ubiquitination of Miro1 is 694	
monitored using fluorescently-labelled ubiquitin (left top). Coomassie stained gel 695	
shows total Miro1 levels (left bottom). Integrated intensities of Miro1-Ub levels 696	
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from three independent experiments were plotted as mean ± SEM (right). 697	
Statistical significance was determined by one-way analysis of variance with 698	
Bonferroni’s multiple-comparison test. (n = 3, ****P < 0.0001, **P < 0.01 ) 699	
 700	
Figure 5 Model of Parkin regulation  701	
a) Parkin is autoinhibited by UBL blocking IBR (brown) and H3 (red) of RING1 702	
(cyan). 703	
b) Phosphorylation (marked with red asterisk) of UBL/pUb binding creates a 704	
pocket at H3-IBR and UBL interface, leading to activated Parkin. 705	
c) Activated Parkin shows small rearrangements triggered by the straightening of 706	
the H3-IBR helix. Loaded E2 (E2~Ub) is recognised at this new interface, E2 707	
occupying interface with REP and RING1 of activated Parkin, Ubdon (grey) sitting 708	
on the interface of IBR (brown box) and H3 (red helix) of RING1 of neighbouring 709	
molecule of Parkin (marked with a dashed line). 710	
 711	
Table 1 712	
Table	1	Data	collection	and	refinement	statistics	(molecular	replacement)	713	 	714	 	 UBLR0RBR+pUb	(5N2W)	 S65DUBLR0RBR+pUb	(5N38)	
Data	collection	 	 	Space	group	 P63	2	2	 P63	2	2	Cell	dimensions  	 	 					a,	b,	c	(Å) 147.3	147.3	87.5	 146.5	146.5	88.4	
    α, β, γ	(°)		 90	90	120	 90	90	120	Resolution	(Å)	 56.34-2.68	(2.81-2.68)a	 72.56-2.60	(2.76-2.60)a	
Rmerge		 10.7	(71.9)														 8.2	(48.4)	
I/σ(I)	 8.9	(1.9)	 9.1	(2.2)	
CC1/2	 99.4	(66.8)												 99.5	(64.0)	Completeness	(%)	 93.6	(93.7)	 96.4	(88.4)	Redundancy	 4.6	(4.2)													 3.5	(3.2)	
	 	 	
Refinement	 	 	Resolution	(Å)	 56.34	(2.68)	 72.56	(2.60)	No.	reflections	 15007	 16984	
Rwork	/	Rfree	 19.93/24.17	 18.16/22.86	
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No.	atoms	 	 					Protein	 3619	 3565					Ligand/ion	 23a	 17b					Water	 29	 46	
B	factors	 	 					Protein	 60.2	 55.9					Ligand/ion	 84.4	 79.1					Water	 53.4	 37.8	R.m.s.	deviations	 	 					Bond	lengths	(Å)	 0.01	 0.01					Bond	angles	(°)	 1.14	 1.17	Single	crystals	were	used	for	structure	determination.	715	 a8	Zinc	ions,	1	Chloride	ion,	10	trimethyloxide	atoms,	4	aminopropane	atoms	716	 b8	Zinc	ions,	1	Chloride	ion,	4	polyethylene	glycol	atoms,	4	aminopropane	atoms717	
	 29	
Online Methods 718	
Protein expression and purification 719	
UBLR0RBRGln347Cys (resi 1-83, 144-465) and S65DUBLR0RBRgln347Cys (resi 720	
1-83, 144-465) were expressed as His-Smt-3 fusion. FL, various mutants and 721	
truncated constructs of Parkin were expressed as His-SUMO fusion. Constructs were 722	
expressed in in BL21 (DE3) E. coli cells and purified as previously described (21,22).  723	
Parkin or ubiquitin were phosphorylated using Pediculus humanus PINK1 (126-C) or 724	
Tribolium castaneum PINK1 (TcPINK1), expressed and purified as previously 725	
described 23,57. Miro1 (181-592) and fluorescently labelled ubiquitin (UbIR800) were 726	
prepared as previously described 23. 727	
 728	
Preparation of phospho-Ubiquitin-3BR probe 729	
Ubiquitin was expressed as ubiquitin 1-75-Mxe-intein/chitin binding domain using 730	
pTXB-1 vector ((DU49003)) in BL21 E. coli cells. Cells were induced at 0.5 OD600 731	
with 300µM IPTG (Isopropyl β-D-1-thiogalactopyranoside) and incubated at 20°C 732	
overnight. Cells were lysed in lysis buffer (20mM Na2HPO4 pH7.2, 200mM NaCl and 733	
0.1mM EDTA). Clear lysate was incubated with Chitin resin, after washing with 2-734	
column volume of lysis buffer protein was eluted in 20mM Na2HPO4 pH6.0, 200mM 735	
NaCl and 0.1mM EDTA and 0.1mM MESNA (Sodium 2-mercaptoethanesulfonate). 736	
Eluted material was reacted with 3-Bromo-propyl amine hydrobromide (SIGMA) as 737	
described before 58,59. After reaction, protein was purified on size-exclusion column 738	
pre-equilibrated with PBS. Fractions containing ubiquitin were collected and 739	
phosphorylated using Pediculus humanus GST-PINK1, and further purified by size-740	
exclusion chromatography. M1-(UbS65A) 3-pUb-3BR was prepared similarly by 741	
expressing M1 linked linear tetra-ubiquitin, in the same vector, with distal ubiquitins’ 742	
Ser65 mutated to Ala. 743	
	 30	
 744	
Preparation of UBLR0RBR347Cys~pUb/S65DUBLR0RBR347Cys~pUb 745	
We first mutated UBLR0RBR Parkin to contain a cysteine residue at position 347. 746	
The corresponding residue in Pediculus humanus Parkin is a cysteine, and this 747	
enabled R0RBR Parkin to react with the phosphoubiquitin-3BR probe, as described 748	
previously 43. UBLR0RBRGln347Cys/S65DUBLR0RBRGln347Cys was reacted 749	
with 3 fold molar excess of pUb-3BR probe at room temperature for 2hrs. Complex 750	
was purified by size-exclusion chromatography in 20mM Tris pH7.5, 75mM NaCl 751	
and 250µM TCEP buffer. UBLR0RBR347Cys~pUb-(M1-UbS65A)3 was prepared 752	
using the same method. 753	
 754	
Crystallisation and Structure determination 755	
UBLR0RBRGln347Cys/S65DUBLR0RBRGln347Cys~pUb were crystallised at 4°C 756	
in sitting drop plates by mixing 1:1 of protein (7mg/ml) and mother liquor (100mM 757	
Tris pH 8.5, 200mM TMAO, PEG MME 2000). Crystals were flash frozen in liquid 758	
nitrogen using 20% of PEG400 as cryo-protectant in the original mother liquor. Data 759	
were collected at Diamond Light Source, wavelength 0.979Å. Data were solved by 760	
molecular replacement program Phaser in CCP4 60 by using UBL (1-76), RING0 761	
(142-216), RING1 (229-328), IBR (329-377) and RING2(Rcat) (415-465) domains of 762	
apo Parkin structure (5c1z) and pUb (4wzp) as ensembles. Solution obtained by 763	
phaser was built and refined in iterative cycles by using coot 61 and autobuster 62, 764	
respectively. Ramachandran values were calculated using Molprobity 63. Both 765	
structures have excellent geometry with ~95% of residues in the most favoured 766	
regions. The structure coordinates and structure factors have been deposited in the 767	
Protein Data Bank, with the accession codes 5N2W and 5N38.  768	
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 769	
Size-exclusion chromatography 770	
Size-exclusion chromatography experiment was performed on analytical column 771	
superdex-75, pre-equilibrated with 50mM HEPES pH 7.5, 200mM NaCl, 250µM of 772	
TCEP. 10µM of Phospho-Parkin was incubated with 2 fold molar excess of pUb or 773	
pUb and UbcH7~Ub for 1 hr prior to loading on column. UbcH7~Ub was prepared as 774	
described previously 23.  775	
 776	
Isothermal titration calorimetry 777	
ITC experiments were performed using PEAQ-ITC (Malvern instruments), and data 778	
were analysed using single-site binding model. 30µM of WT-Phospho-779	
Parkin/Phospho-ParkinGlu321Ala (premixed with 1.2 fold molar excess of pUb) were 780	
titrated using 1.6mM or 1.48mM of UbcH7 in the syringe, respectively. 21.4µM of 781	
ΔUBL, 40µM of ΔUBL (Gln389Ala, Tyr291Ala, Arg392Ala) premixed with 1.2 fold 782	
molar excess of pUb, and 19µM of ΔUBL-ΔIBR were titrated using 1.14mM, 750µM, 783	
500µM of WT UBL domain in the syringe, respectively. UbcH7 and UBL titrations 784	
were performed at 20°C in 50mM HEPES pH 7.5, 200mM NaCl, 250µM of TCEP 785	
and PBS, 500µM of TCEP, respectively. 786	
 787	
Ubiquitination assay 788	
Ubiquitination reactions were performed at 30°C in 50mM Tris pH 7.5, 100mM 789	
NaCl, 2.5mM Mgcl2, 5% glycerol, 500µM TCEP. Ubiquitin chain extension reactions 790	
contained 25nm of recombinant human E1, 500nM of UbcH7, 1µM E3 and 5mM of 791	
ATP in 20 µl of final reaction volume. 0.5 µM of pUB/ WT-UB was used as an 792	
allosteric activator in various reactions. Ubiquitination reaction was analysed using 793	
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3µM of fluorescently labelled ubiquitin (UbIR800). Ubiquitin labelling was performed 794	
using DyLightTM 800 Maleimide as described before 23. Miro1 ubiquitination was 795	
performed in the similar setup using 5µM of Miro1 (181-592) and 12.5nm of 796	
recombinant human E1, 250nM of UbcH7, 0.5µM E3 and 5mM of ATP in 20 µl of 797	
final reaction volume. For Figure 3d, UBS65A/WT-798	
Ub/UbcH7C86K/UbcH7C86K~Ub were phosphorylated in separate reactions with 799	
GST tagged TcPINK1; UbcH7C86K~Ub with no PINK1 was used as control. Prior to 800	
addition to Ubiquitination reaction, PINK1 was depleted using GST resin. 801	
Miro1 ubiquitination was performed in the similar setup using 5µM of Miro1 (181-802	
592) and 12.5nm of recombinant human E1, 250nM of UbcH7, 0.5µM (unless 803	
otherwise specified) E3 and 5mM of ATP in 20 µl of final reaction volume. All 804	
assays were repeated at least 3 times. 805	
 806	
Parkin ubiquitin loading 807	
Reactions monitoring RING2(Rcat)-ubiquitin ester formation were performed at 30°C 808	
for 90 min in 50mM Tris pH 7.5, 100mM NaCl, 5mM MgCl2, 1mM TCEP and 0.5% 809	
polyethylene glycol 6000 reaction buffer. Reactions contained 50nm E1, 10µM 810	
UbcH7, 10µM UbIR800, 3µM E3 and 5mM ATP in final reaction volume of 10µl. Non-811	
activatable pUb-6His (3µM) was used as an allosteric activator where indicated. 812	
Reactions were stopped using NuPAGE LDS Sample Buffer (Invitrogen) that 813	
contained reducing agents and boiled for 5min. To hydrolyse ester linkages the boiled 814	
samples were cooled and further treated with 0.4M NaOH for 20 min at 42°C. The 815	
samples were resolved by SDS-PAGE and analyzed by direct fluorescence 816	
monitoring using Li-COR Odyssey Infrared Imaging System. Integrated intensities of 817	
Parkin-Ub ester species from three independent experiments were obtained using 818	
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Image Studio (Odyssey) imaging software, plotted as mean ± standard error of mean 819	
(SEM) and statistically analysed using GraphdPad Prism7. 820	
 821	
Chemical Shift Perturbations 822	
A complex of 2H,12C,15N-labelled R0RBR with 2H-labelled pUb (prepared as above) 823	
was purified to homogeneity using gel filtration chromatography in 25 mM HEPES, 824	
100 mM NaCl, 0.5 mM TCEP at pH 7.0. Chemical shift perturbation experiments 825	
were measured using 1H,15N-TROSY spectra of 205 µM 2H,12C,15N-R0RBR/ 2H-pUb 826	
in the absence and presence of 2H,14N-labelled Ub. These experiments were 827	
quantified using the following weighted formula: ((0.2 × ΔδN2) + ΔδH2 )1/2 and 828	
plotted as a function of residue. All NMR experiments were collected using a triple 829	
resonance cryogenic probe on a Varian Inova 600 MHz NMR spectrometer at 25˚C. 830	
 831	
Accession codes 832	
The protein structure files reported in this manuscript are available from the Protein 833	
Data Bank with accession codes 5N2W, and 5N38. 834	
 835	
Data availability statement 836	
All constructs are available on request from the MRC Protein Phosphorylation and 837	
Ubiquitylation Unit reagents Web page (http://mrcppureagents.dundee.ac.uk). All 838	
other data are available from corresponding author upon reasonable request. 839	
 840	
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Supplementary Figure 1  
UBL and RING1 interface remain associated in the complex structures of Parkin and pUb  
a) Asymmetric Unit of crystal structure of UBLR0RBR and pUb complex showing UBL (green), RING1 (cyan), IBR (brown), REP 
(yellow), and RING2(Rcat) (red) of one molecule, RING0 (magenta) and pUb (blue) from another molecule (upper panel). The interface 
between the two molecules is marked with  a solid line. The biological unit of active Parkin complexed with pUb is generated using 
domains from symmetry-related molecules of Parkin (Lower panel). The phosphate group of pUb is shown in stick representation. b) 
Superposition of UBLR0RBR-pUb complex structure, UBL (green), RING1 (cyan), REP (yellow), with apo structure of UBLR0RBR 
(grey) (pdb code: 5C1Z). Important residues at UBL-RING1 interface, and the tether connecting IBR and REP are shown as sticks. 
UBLR0RBR-pUb complex structure showing alternate conformations of flexible loop (62-65) movement is marked with dashed line, 
Ser65 is shown as stick. c) Superposition of UBLR0RBR-pUb complex structure coloured as in b, with the S65DUBLR0RBR-pUb 
complex structure (grey). Important residues in the tether and the UBL-IBR interface are shown as sticks in the close-up (right). d) 
Isothermal Titration Calorimetry assays showing UBL interaction with UBL Parkin tether mutants (Q389A, Y391A, R392A) in the 
absence (left) and presence (right) of phosphoubiquitin. Tether mutants (Q389A, Y391A, R392A) in UBL Parkin do not rescue the loss 
of UBL and Parkin association in the presence of pUb). e) Electrostatic charge surface of Parkin showing negatively charged region at 
the interface of UBL and IBR, Ser65 on UBL is shown as stick. The electrostatic potential is calculated with the program APBS (Baker 
NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc 
Natl Acad Sci USA. 2001 98(18):10037-41.). The surface is coloured with a blue to red gradient from +2.5 to −2.5 KbT/e. 
 
 
 
 
Supplementary Figure 2 
Phosphoubiquitin binding to Parkin reveals cryptic ubiquitin binding sites  
a) Comparison of apo structure of UBLR0RBR (left) with UBLR0RBR-pUb complex (right). The surface representation shows the void 
created between the IBR (brown) and UBL (green) domains upon phosphoubiquitin (blue) binding. For clarity the rest of Parkin is shown 
in grey, with domains labelled. b) The void created between IBR (brown) and UBL (green) is occupied by a symmetry related molecule 
2 of Parkin, mediated by UBL (yellow) of the second molecule. The second Parkin molecule is outlined (left), with the rest of Parkin 
shown in grey for clarity. A second cartoon view related by a ~90o rotation around the y-axis shows the UBL of molecule 2 (yellow) 
nestling between the UBL (green) and IBR (brown) of molecule 1. Phosphoubiquitin is shown in blue. The crystal symmetry axis 
between the two molecules is represented by a dashed line. c) Massive enhancement in ubiquitin chain formation and Parkin 
autoubiquitination activity of Parkin upon UBLR0RBRCys347 linkage with (M1-UbS65A)3-pUb-3BR probe (left panel). 
UBLR0RBRCys347 reaction with suicide probes (pUb-3BR/(M1-UbS65A) 3-pUb-3BR) is shown (right panel), reacted species of 
UBLR0RBR347Cys with suicide probe is marked with *. 
 
 
 
 
Supplementary Figure 3 
Phosphoubiquitin binding enables recruitment of the charged E2, UbcH7~Ub 
a) Size-exclusion chromatography of phosphoParkinE321A and pUb complex does not show any shift with UbcH7~Ub isopeptide, WT-
phosphoParkin and pUb results in a shift and co-elutes with charged E2, fractions were confirmed by SDS PAGE analysis. b) 
Isothermal titration calorimetry shows that ParkinE321A associates with phosphoubiquitin with the same affinity as wild-type Parkin. 
 
 
 
 
 
Supplementary Figure 4 
Model of phosphoubiquitin-bound Parkin in complex with donor ubiquitin  
a) The UblR0RBR structure in complex with phosphoubiquitin, coloured as in Figure 1a with all domains labelled, is modelled with a 
ubiquitin moiety in the H3-IBR binding site. The model is based on a combination of the crystallographically related UBL domain, the 
HOIP RBR/E2~Ub structure, and the chemical shift perturbations showing the ubiquitin binding site on Parkin. An arrow indicates the 
route from the tail of the ubiquitin molecule to the catalytic cysteine in the RING2(Rcat) domain. b) Ubiquitination assay following the 
ubiquitination of Miro1 in the presence of increasing concentrations of inactive UblR0RBR Parkin, or UblR0RBR covalently linked to 
phosphoubiquitin. Activity is monitored following fluorescently labelled ubiquitin, and a coomassie stained gel shows input levels. 
 
 
 
 
Supplementary Figure 5 
Arrangements of domains in RBR modules suggests a common mode of regulation whereby the IBR and RING2(Rcat) of 
RBRs recruit multiple ubiquitin-like molecules  
a) Structural arrangement of RING1-IBR-RING2(Rcat) Domain in Parkin (upper panel, pdb code 5C1Z), HOIP (middle panel, pdb code 
4KBL), and HHARI (lower panel, pdb code 5EDV). b) Autoinhibited structure of HHARI (pdb code 4KBL), proposed E2 binding site and 
NEDD8 binding site are highlighted in yellow and blue circles, respectively. c) Superposition of H3-IBR of Parkin (brown, PDB code 
5C1Z) and HHARI (black, PDB code 4KBL) in the autoinhibited state, compactness between helix (H3) and IBR is marked with an 
arrow. d) Superposition of H3-IBR of Parkin (brown, UBLR0RBR-pUb complex) and HOIP (cyan, PDB code: 5EDV) in the active state, 
with overlapping positions for activator ubiquitin (Uballo /pUb, blue) and donor ubiquitin (Ubdon, salmon red). e) Representation of the 
asymmetric unit of the crystal structure of HOIP in complex with E2~Ub and activator ubiquitin (Uballo) (pdb code 5EDV). The 
asymmetric unit contains two molecules of HOIP (green, cyan), E2 (yellow), donor ubiquitin (Ubdon, salmon), activator ubiquitin (Uballo, 
blue circle). RING1, IBR and RING2(Rcat) domains are circled with dashed line, distance between catalytic cysteine of RING2(Rcat), 
Cys885 (brown circle), and RING1 (P707) of the same molecule is represented by straight solid line. Catalytic cysteine, Cys86, of E2 is 
represented as black circle. Processive unit of HOIP (marked with dashed line) is formed by RING1-IBR from one molecule of HOIP, 
RING2(Rcat) from another molecule of HOIP interacting with E2, Ubdon and Uballo, f) IBR (cyan) of HOIP (pdb code 5EDV) interacting 
with activator ubiquitin (Uballo, blue) and donor ubiquitin (Ubdon, salmon red), left panel.IBR (brown) of Parkin (UBLR0RBR-pUb 
complex) interacting with pUb (blue) and donor ubiquitin (Ubdon, grey), right panel.g) RING2L/Rcat (cyan) of HOIP (pdb code 4LJP) 
interacting with donor ubiquitin (Ubdon, salmon red) and acceptor ubiquitin (pale cyan), left panel. RING2(Rcat) (brown) of Parkin 
(UBLR0RBR-pUb complex) interacting with donor ubiquitin (Ubdon, grey), right panel. 
 
 
 
